Tagrisso, Imfinzi, Truqap, and Enhertu all reported double-digit sales growth during the fourth quarter and full-year 2025 ...

The firm will test the FSHR-targeting lira-cel at up to 100-tmes higher doses after seeing better than expected outcomes at ...

NEW YORK – Yatiri Bio's artificial intelligence-based proteomic platform is giving new hope to a SMARCA2/4 inhibitor program that Foghorn Therapeutics previously halted. After seeing Yatiri's ability ...

The FDA raised concerns about multiple facets of the study protocol used to evaluate RGX-121, including the eligibility criteria and surrogate endpoints.

It is the first CAR-T that the agency has said is safe for this hard-to-treat subset of lymphoma patients based on data from an investigator-initiated study.

NEW YORK – Eli Lilly on Monday said it will acquire in vivo CAR T-cell therapy developer Orna Therapeutics to strengthen its R&D work in genetic medicine and in vivo cell engineering.

Biogen's "growth products" — about a half-dozen products including Leqembi — contributed $800 million to the firm's $2.28 ...

Dementia care isn't just about new drugs, said the author of a cost-effectiveness study comparing collaborative care, Leqembi ...

Despite another quarter of declining sales for Ibrance, its top-selling oncology drug, revenue for Pfizer's overall oncology ...

Lilly will license programmable recombinases developed by Seamless to create new gene-editing therapies that could treat ...

The firm provided updates alongside Q4 and full-year 2025 financial results, and reported $19.29 billion and $65.18 billion ...

The firm is hoping to make up for revenue lost to generic competition in coming years by growing adoption of treatments like ...